Immunochemistry analyzer sales will rise through 2036, driven by chemiluminescence immunoassay at 42.7% of the product type segment in 2026, supported by increasing clinical adoption and expanding procedural volume. The market was valued at USD 25.66 billion in 2025 and is expected to be worth USD 128.84 billion by 2036.